Real‐world usage of paliperidone palmitate injection

A challenge in achieving clinical remission in patients with schizophrenia lies in the high rate of antipsychotic discontinuation, often resulting in relapse, characterized by exacerbation of symptomatology, deterioration in functional activities, and the emergence of treatment resistance. Long‐acting antipsychotics have been developed to help reduce medication nonadherence and minimize relapse. One of the most widely used of these drugs is paliperidone palmitate, a long‐acting injectable (LAI) formulation of paliperidone (an active metabolite of risperidone).